{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T10:36:29Z","timestamp":1777545389455,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biotechnol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12896-018-0443-0","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T12:38:46Z","timestamp":1527597526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The production of a recombinant tandem single chain fragment variable capable of binding prolamins triggering celiac disease"],"prefix":"10.1186","volume":"18","author":[{"given":"Britta","family":"Eggenreich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Johannes","family":"Wurm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Forster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0916-0644","authenticated-orcid":false,"given":"Oliver","family":"Spadiut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,29]]},"reference":[{"issue":"5","key":"443_CR1","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.jaci.2015.01.044","volume":"135","author":"PHR Green","year":"2015","unstructured":"Green PHR, Lebwohl B, Greywoode R. Celiac disease. J Allergy Clin Immunol. 2015;135(5):1099\u2013106.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"443_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00394-016-1238-5","volume":"56","author":"KA Bascunan","year":"2017","unstructured":"Bascunan KA, Vespa MC, Araya M. Celiac disease: understanding the gluten-free diet. Eur J Nutr. 2017;56(2):449\u201359.","journal-title":"Eur J Nutr"},{"issue":"6","key":"443_CR3","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1053\/j.gastro.2009.09.008","volume":"137","author":"D Schuppan","year":"2009","unstructured":"Schuppan D, Junker Y, Barisani D. Celiac disease: from pathogenesis to novel therapies. Gastroenterology. 2009;137(6):1912\u201333.","journal-title":"Gastroenterology"},{"issue":"6","key":"443_CR4","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/ajg.2016.105","volume":"111","author":"M Wungjiranirun","year":"2016","unstructured":"Wungjiranirun M, Kelly CP, Leffler DA. Current status of celiac disease drug development. Am J Gastroenterol. 2016;111(6):779\u201386.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"443_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrgastro.2013.141","volume":"11","author":"K Kaukinen","year":"2014","unstructured":"Kaukinen K, Lindfors K, Maki M. Advances in the treatment of coeliac disease: an immunopathogenic perspective. Nat Rev Gastroenterol Hepatol. 2014;11(1):36\u201344.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"443_CR6","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrgastro.2010.23","volume":"7","author":"GJ Tack","year":"2010","unstructured":"Tack GJ, Verbeek WH, Schreurs MW, Mulder CJ. The spectrum of celiac disease: epidemiology, clinical aspects and treatment. Nat Rev Gastroenterol Hepatol. 2010;7(4):204\u201313.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"443_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2147\/CEG.S87200","volume":"9","author":"J Woodward","year":"2016","unstructured":"Woodward J. Improving outcomes of refractory celiac disease - current and emerging treatment strategies. Clin Exp Gastroenterol. 2016;9:225\u201336.","journal-title":"Clin Exp Gastroenterol"},{"issue":"10","key":"443_CR8","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nrgastro.2015.155","volume":"12","author":"T van Gils","year":"2015","unstructured":"van Gils T, Nijeboer P, van Wanrooij RL, Bouma G, Mulder CJ. Mechanisms and management of refractory coeliac disease. Nat Rev Gastroenterol Hepatol. 2015;12(10):572\u20139.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"443_CR9","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1517\/13543784.2014.916274","volume":"23","author":"K Kurppa","year":"2014","unstructured":"Kurppa K, Hietikko M, Sulic AM, Kaukinen K, Lindfors K. Current status of drugs in development for celiac disease. Expert Opin Investig Drugs. 2014;23(8):1079\u201391.","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"443_CR10","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1177\/2472555217697435","volume":"1","author":"H Hundsberger","year":"2017","unstructured":"Hundsberger H, Koppensteiner A, Hofmann E, Ripper D, Pfluger M, Stadlmann V, Klein CT, Kreiseder B, Katzlinger M, Eger A, et al. A screening approach for identifying Gliadin neutralizing antibodies on epithelial intestinal Caco-2 cells. SLAS Discov. 2017;1(8):1035\u201343.","journal-title":"SLAS Discov"},{"key":"443_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12896-015-0223-z","volume":"15","author":"V Stadlmann","year":"2015","unstructured":"Stadlmann V, Harant H, Korschineck I, Hermann M, Forster F, Missbichler A. Novel avian single-chain fragment variable (scFv) targets dietary gluten and related natural grain prolamins, toxic entities of celiac disease. BMC Biotechnol. 2015;15:109.","journal-title":"BMC Biotechnol"},{"issue":"9","key":"443_CR12","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/nbt1142","volume":"23","author":"P Holliger","year":"2005","unstructured":"Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23(9):1126\u201336.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"443_CR13","first-page":"485","volume":"58","author":"GP Adams","year":"1998","unstructured":"Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 1998;58(3):485\u201390.","journal-title":"Cancer Res"},{"key":"443_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/978-1-60327-302-2_17","volume":"562","author":"L Guglielmi","year":"2009","unstructured":"Guglielmi L, Martineau P. Expression of single-chain Fv fragments in E. Coli cytoplasm. Methods Mol Biol. 2009;562:215\u201324.","journal-title":"Methods Mol Biol"},{"issue":"7","key":"443_CR15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.4014\/jmb.1412.12079","volume":"25","author":"MN Baeshen","year":"2015","unstructured":"Baeshen MN, Al-Hejin AM, Bora RS, Ahmed MM, Ramadan HA, Saini KS, Baeshen NA, Redwan EM. Production of biopharmaceuticals in E. Coli: current scenario and future perspectives. J Microbiol Biotechnol. 2015;25(7):953\u201362.","journal-title":"J Microbiol Biotechnol"},{"key":"443_CR16","first-page":"172","volume":"5","author":"GL Rosano","year":"2014","unstructured":"Rosano GL, Ceccarelli EA. Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol. 2014;5:172.","journal-title":"Front Microbiol"},{"issue":"1","key":"443_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12934-015-0222-8","volume":"14","author":"A Singh","year":"2015","unstructured":"Singh A, Upadhyay V, Upadhyay AK, Singh SM, Panda AK. Protein recovery from inclusion bodies of Escherichia coli using mild solubilization process. Microb Cell Factories. 2015;14(1):41.","journal-title":"Microb Cell Factories"},{"issue":"4","key":"443_CR18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1263\/jbb.99.303","volume":"99","author":"SM Singh","year":"2005","unstructured":"Singh SM, Panda AK. Solubilization and refolding of bacterial inclusion body proteins. J Biosci Bioeng. 2005;99(4):303\u201310.","journal-title":"J Biosci Bioeng"},{"issue":"1","key":"443_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/biom4010235","volume":"4","author":"H Yamaguchi","year":"2014","unstructured":"Yamaguchi H, Miyazaki M. Refolding techniques for recovering biologically active recombinant proteins from inclusion bodies. Biomolecules. 2014;4(1):235\u201351.","journal-title":"Biomolecules"},{"key":"443_CR20","doi-asserted-by":"publisher","unstructured":"Alibolandi M, Mirzahoseini H. Chemical assistance in refolding of bacterial inclusion bodies. Biochem Res Int. 2011; https:\/\/doi.org\/10.1155\/2011\/631607 .","DOI":"10.1155\/2011\/631607"},{"issue":"9","key":"443_CR21","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2217\/nnm.12.100","volume":"7","author":"A Villaverde","year":"2012","unstructured":"Villaverde A. Bacterial inclusion bodies: an emerging platform for drug delivery and cell therapy. Nanomedicine (Lond). 2012;7(9):1277\u20139.","journal-title":"Nanomedicine (Lond)"},{"issue":"20","key":"443_CR22","doi-asserted-by":"publisher","first-page":"8721","DOI":"10.1007\/s00253-016-7620-7","volume":"100","author":"DJ Wurm","year":"2016","unstructured":"Wurm DJ, Veiter L, Ulonska S, Eggenreich B, Herwig C, Spadiut O. The E. Coli pET expression system revisited\u2014mechanistic correlation between glucose and lactose uptake. Appl Microbiol Biotechnol. 2016;100(20):8721\u20139.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"1","key":"443_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/(SICI)1097-0290(19991005)65:1<54::AID-BIT7>3.0.CO;2-R","volume":"65","author":"MP DeLisa","year":"1999","unstructured":"DeLisa MP, Li J, Rao G, Weigand WA, Bentley WE. Monitoring GFP-operon fusion protein expression during high cell density cultivation of Escherichia coli using an on-line optical sensor. Biotechnol Bioeng. 1999;65(1):54\u201364.","journal-title":"Biotechnol Bioeng"},{"issue":"1","key":"443_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12934-017-0749-y","volume":"16","author":"B Eggenreich","year":"2017","unstructured":"Eggenreich B, Rajamanickam V, Wurm DJ, Fricke J, Herwig C, Spadiut O. A combination of HPLC and automated data analysis for monitoring the efficiency of high-pressure homogenization. Microb Cell Factories. 2017;16(1):134.","journal-title":"Microb Cell Factories"},{"issue":"12","key":"443_CR25","doi-asserted-by":"publisher","first-page":"23658","DOI":"10.3390\/ijms151223658","volume":"15","author":"H-N Song","year":"2014","unstructured":"Song H-N, Jang J-H, Kim Y-W, Kim D-H, Park S-G, Lee MK, Paek S-H, Woo E-J. Refolded scFv antibody fragment against myoglobin shows rapid reaction kinetics. Int J Mol Sci. 2014;15(12):23658\u201371.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"443_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.pep.2013.10.002","volume":"92","author":"D Bu","year":"2013","unstructured":"Bu D, Zhou Y, Tang J, Jing F, Zhang W. Expression and purification of a novel therapeutic single-chain variable fragment antibody against BNP from inclusion bodies of Escherichia coli. Protein Expr Purif. 2013;92(2):203\u20137.","journal-title":"Protein Expr Purif"},{"key":"443_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1475-2859-4-27","volume":"4","author":"E Garcia-Fruitos","year":"2005","unstructured":"Garcia-Fruitos E, Gonzalez-Montalban N, Morell M, Vera A, Ferraz RM, Aris A. Aggregation as bacterial inclusion bodies does not imply inactivation of enzymes and fluorescent proteins. Microb Cell Factories. 2005;4:27.","journal-title":"Microb Cell Factories"},{"issue":"17","key":"443_CR28","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1023\/A:1025024104862","volume":"25","author":"A Villaverde","year":"2003","unstructured":"Villaverde A, Mar Carri\u00f3 M. Protein aggregation in recombinant bacteria: biological role of inclusion bodies. Biotechnol Lett. 2003;25(17):1385\u201395.","journal-title":"Biotechnol Lett"},{"issue":"1","key":"443_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jbiotec.2006.02.026","volume":"125","author":"NS de Groot","year":"2006","unstructured":"de Groot NS, Ventura S. Protein activity in bacterial inclusion bodies correlates with predicted aggregation rates. J Biotechnol. 2006;125(1):110\u20133.","journal-title":"J Biotechnol"},{"key":"443_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1475-2859-9-66","volume":"9","author":"\u0160 Peternel","year":"2010","unstructured":"Peternel \u0160, Komel R. Isolation of biologically active nanomaterial (inclusion bodies) from bacterial cells. Microb Cell Factories. 2010;9:66.","journal-title":"Microb Cell Factories"},{"issue":"2","key":"443_CR31","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3748\/wjg.v20.i2.384","volume":"20","author":"MHJ El-Salhy","year":"2014","unstructured":"El-Salhy MHJ, Hausken T. Is irritable bowel syndrome a stem cell disorder? World J Gastroenterol. 2014;20(2):384\u2013400.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"443_CR32","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.3390\/nu5104250","volume":"5","author":"I Comino","year":"2013","unstructured":"Comino I, de Lourdes Moreno M, Real A, Rodr\u00edguez-Herrera A, Barro F, Sousa C. The gluten-free diet: testing alternative cereals tolerated by celiac patients. Nutrients. 2013;5(10):4250\u201368.","journal-title":"Nutrients"},{"issue":"7","key":"443_CR33","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1365-2036.2012.05013.x","volume":"35","author":"S Rashtak","year":"2012","unstructured":"Rashtak S, Murray JA. Review article: coeliac disease, new approaches to therapy. Aliment Pharmacol Ther. 2012;35(7):768\u201381.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"443_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4161\/mabs.2.1.10786","volume":"2","author":"AL Nelson","year":"2010","unstructured":"Nelson AL. Antibody fragments: hope and hype. MAbs. 2010;2(1):77\u201383.","journal-title":"MAbs"},{"issue":"5","key":"443_CR35","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00253-008-1611-2","volume":"80","author":"T Matsui","year":"2008","unstructured":"Matsui T, Sato H, Yamamuro H, Shinzato N, Matsuda H, Misawa S, Sato S. High cell density cultivation of recombinant E. Coli for hirudin variant 1 production by temperature shift controlled by pUC18-based replicative origin. Appl Microbiol Biotechnol. 2008;80(5):779\u201383.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"1","key":"443_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12934-014-0141-0","volume":"13","author":"NA Baeshen","year":"2014","unstructured":"Baeshen NA, Baeshen MN, Sheikh A, Bora RS, Ahmed MMM, Ramadan HAI, Saini KS, Redwan EM. Cell factories for insulin production. Microb Cell Factories. 2014;13(1):141.","journal-title":"Microb Cell Factories"},{"issue":"7","key":"443_CR37","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1590\/1414-431X20143276","volume":"47","author":"H Sun","year":"2014","unstructured":"Sun H, Wu GM, Chen YY, Tian Y, Yue YH, Zhang GL. Expression, production, and renaturation of a functional single-chain variable antibody fragment (scFv) against human ICAM-1. Braz J Med Biol Res. 2014;47(7):540\u20137.","journal-title":"Braz J Med Biol Res"},{"issue":"1","key":"443_CR38","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1006\/prep.2002.1624","volume":"25","author":"Z Gu","year":"2002","unstructured":"Gu Z, Weidenhaupt M, Ivanova N, Pavlov M, Xu B, Su Z-G, Janson J-C. Chromatographic methods for the isolation of, and refolding of proteins from, Escherichia coli inclusion bodies. Protein Expr Purif. 2002;25(1):174\u20139.","journal-title":"Protein Expr Purif"}],"container-title":["BMC Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-018-0443-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12896-018-0443-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-018-0443-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T14:40:20Z","timestamp":1661352020000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbiotechnol.biomedcentral.com\/articles\/10.1186\/s12896-018-0443-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,29]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["443"],"URL":"https:\/\/doi.org\/10.1186\/s12896-018-0443-0","relation":{},"ISSN":["1472-6750"],"issn-type":[{"value":"1472-6750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,29]]},"assertion":[{"value":"13 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Sciotec Diagnostic Technologies GmbH holds a patent for the use of IgY and fragments thereof in CD therapy. FF and ES were employed by Sciotec Diagnostic Technologies GmbH, when this study was conducted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"30"}}